Compare Invesco NASDAQ 100 ETF (QQQM) vs Sana Biotechnology Inc (SANA) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Invesco NASDAQ 100 ETF vs Sana Biotechnology Inc — how do they compare? Invesco NASDAQ 100 ETF trades at $294.97, while Sana Biotechnology Inc trades at $3.24 (market cap $1.03B). The key difference: Invesco NASDAQ 100 ETF is trading nearer its 52-week high, Sana Biotechnology Inc nearer its low. Which is the better fit depends on your goals.
| QQQM | SANA | |
|---|---|---|
Sector | Broad Market / Factor | Health |
52-Week High | $307.23 | $5.92 |
52-Week Low | $229.87 | $2.68 |
Market Cap | — | $1.03B |
Enterprise Value | — | $946.04M |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
QQQM trades at $295.76, down 0.1% with a bullish technical signal from moving averages. The ETF tracks the Nasdaq-100 index, offering diversified exposure to large-cap growth stocks. Recent news highlights QQQM's low expense ratio advantage over QQQ and its position as a core growth allocation option for investors seeking Nasdaq-100 exposure.
The outlook remains positive for long-term growth investors, with technical indicators supporting bullish momentum. Key risks include concentration in top holdings and market sensitivity to technology sector performance. The ETF's low-cost structure provides a competitive advantage for sustained investment.
SANA Biotechnology trades at $3.45, down 10.39% in the past 24 hours, reflecting bearish technical signals and negative profitability. The company reported a net loss of $244.17 million for 2025, with a price-to-book ratio of 6.68. Recent news includes investor conference presentations and a peer-reviewed publication in The New England Journal of Medicine highlighting clinical data.
Despite analyst consensus favoring a 'Buy' rating (81.82% of 11 analysts), the stock faces significant risks from negative cash flows, high losses, and potential fiduciary concerns. Upside hinges on successful clinical developments and improved financial performance, but current fundamentals suggest caution for investors.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Invesco NASDAQ 100 ETF
QQQM is an ETF designed to track the performance of the NASDAQ-100 Index. It provides exposure to the 100 largest non-financial companies listed on the NASDAQ. Positioned as a lower-cost and more long-term-investor-friendly alternative to its peer QQQ, QQQM offers the same fundamental market exposure but typically has a lower share price and is structured to appeal to investors focused on accumulation rather than active trading.
Read more on QQQM →About Sana Biotechnology Inc
Sana Biotechnology Inc. is a clinical-stage biopharmaceutical company focused on creating and delivering engineered cells as medicines for patients. The company is developing cell therapies for various diseases, including oncology, diabetes, and central nervous system disorders. Sana's core strategy is built around two key technological platforms: in vivo gene delivery to repair cells inside the body and ex vivo cell engineering for therapeutic use.
Read more on SANA →
